NCT00661440

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.

Conditions

• Nystagmus, Congenital Idiopathic
• Nystagmus, Acquired

Interventions

Type	Name	Description
DRUG	Neramexane mesylate	2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day

Timeline

• Start date: 2008-05-01
• First posted: 2008-04-18
• Last updated: 2009-11-26

Locations

1 site across 1 country: United Kingdom